在前瞻性177Lu-PSMA-617与NOX66联合试验(LuPIN)中评估177Lu-PSMA-617 SPECT/CT定量作为疗效生物标志物
LuPIN试验纳入56例既往接受化疗和新型雄激素信号抑制剂治疗的进展性mCRPC男性,接受最多6剂177Lu-PSMA-617与放射增敏剂NOX66。32例在第1和第3周期均有可分析系列177Lu SPECT,PSA 50%缓解率63%(20/32),SPECT总肿瘤体积任何增加与更短PSA PFS相关(HR 4.1,95%CI 1.5-11.2,P=0.006)。结论认为定量177Lu SPECT上SPECT TTV增加预测短PFS,未来可能作为影像疗效生物标志物。
要点
- 32例可分析患者中PSA 50%缓解率为63%(20/32),中位PSA PFS 6.3个月(95%CI 5-10个月)。
- SPECT TTV任何增加与更短PSA PFS相关(HR 4.1,95%CI 1.5-11.2,P=0.006)。
- 肿瘤SUVmax和SUVmean降低均与PSA PFS或总生存结局无关。
核心结论
- 定量177Lu SPECT上SPECT TTV增加预测短PFS,未来可能作为影像疗效生物标志物。
研究设计与样本
- LuPIN前瞻性试验纳入56例进展性mCRPC男性,既往接受过化疗和新型雄激素信号抑制剂,接受最多6剂177Lu-PSMA-617与放射增敏剂NOX66。
- 研究入组和退出时行68Ga-PSMA-11和18F-FDG PET/CT,每剂治疗后24小时行从头顶至大腿中部的177Lu SPECT。
- 在第1周期(基线)和第3周期(第12周)进行SPECT定量分析。
主要发现
- 56例中32例在第1和第3周期均有可分析系列177Lu SPECT;该亚组中位PSA PFS为6.3个月(95%CI 5-10个月),中位总生存为12.3个月(95%CI 12-24个月)。
- 该亚组PSA 50%缓解率为63%(20/32)。
- SPECT TTV在68%(22/32)患者中缩小(中位-0.20 m3,95%CI -1.4至-0.001),在31%(10/32)患者中增大(中位0.36,95%CI 0.1-1.4)。
- SPECT TTV任何增加与更短PSA PFS相关(HR 4.1,95%CI 1.5-11.2,P=0.006);SPECT TTV增加30%或以上也与更短PSA PFS相关(HR 3.3,95%CI 1.3-8.6,P=0.02)。
- 肿瘤SUVmax在91%(29/32)患者中降低、SUVmean在84%(27/32)患者中降低,两者均与PSA PFS或总生存结局无关;第12周PSA进展与更短PSA PFS相关(HR 26.5,95%CI 5.4-131)。
关键数值与推荐
- 第12周SPECT TTV进展的10例患者中,50%(5/10)无同期PSA进展(中位PSA PFS 4.5个月,95%CI 2.8-5.6个月),5/10例在第12周同时有PSA和SPECT TTV进展(中位PSA PFS 2.8个月,95%CI 1.8-3.7个月)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
177Lu-PSMA-617 is an effective and novel treatment in metastatic castration-resistant prostate cancer (mCRPC). Our ability to assess response rates and therefore efficacy may be improved using predictive tools. This study investigated the predictive value of serial 177Lu-PSMA-617 SPECT/CT (177Lu SPECT) imaging in monitoring treatment response. Methods: Fifty-six men with progressive mCRPC previously treated with chemotherapy and novel androgen signaling inhibitor were enrolled into the LuPIN trial and received up to 6 doses of 177Lu-PSMA-617 and a radiation sensitizer (3-(4-hydroxyphenyl)-2H-1-benzopyran-7-ol [NOX66]). 68Ga-PSMA-11 and 18F-FDG PET/CT were performed at study entry and exit, and 177Lu SPECT from vertex to mid thighs was performed 24 h after each treatment. SPECT quantitative analysis was undertaken at cycles 1 (baseline) and 3 (week 12) of treatment. Results: Thirty-two of the 56 men had analyzable serial 177Lu SPECT imaging at both cycle 1 and cycle 3. In this subgroup, median prostate-specific antigen (PSA) progression-free survival (PFS) was 6.3 mo (95% CI, 5-10 mo) and median overall survival was 12.3 mo (95% CI, 12-24 mo). The PSA 50% response rate was 63% (20/32). 177Lu SPECT total tumor volume (SPECT TTV) was reduced in 68% (22/32; median, -0.20 m3 [95% CI, -1.4 to -0.001]) and increased in 31% (10/32; median, 0.36 [95% CI, 0.1-1.4]). Any increase in SPECT TTV was associated with shorter PSA PFS (hazard ratio, 4.1 [95% CI, 1.5-11.2]; P = 0.006). An increase of 30% or more in SPECT TTV was also associated with a shorter PSA PFS (hazard ratio, 3.3 [95% CI, 1.3-8.6]; P =0.02). Tumoral SUVmax was reduced in 91% (29/32) and SUVmean in 84% (27/32); neither was associated with PSA PFS or overall survival outcomes. PSA progression by week 12 was also associated with a shorter PSA PFS (hazard ratio, 26.5 [95% CI, 5.4-131]). In the patients with SPECT TTV progression at week 12, 50% (5/10) had no concurrent PSA progression (median PSA PFS, 4.5 mo [95% CI, 2.8-5.6 mo]), and 5 of 10 men had both PSA and SPECT TTV progression at week 12 (median PSA PFS, 2.8 mo [95% CI, 1.8-3.7 mo]). Conclusion: Increasing SPECT TTV on quantitative 177Lu SPECT predicts a short PFS and may play a future role as an imaging response biomarker.
引用
- Pathmanandavel S, Crumbaker M, Ho B, et al. Evaluation of 177Lu-PSMA-617 SPECT/CT Quantitation as a Response Biomarker Within a Prospective 177Lu-PSMA-617 and NOX66 Combination Trial (LuPIN). J Nucl Med. 2022. PMID: 36008120. doi:10.2967/jnumed.122.264398
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。